Dec 19, 2006 – PsychoGenics Inc. today announced that it has entered into a drug discovery and development agreement with Eli Lilly and Company (NYSE: LLY). Per the agreement, Lilly will provide drug candidates that PsychoGenics will evaluate, using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders.